Metagenomi, Inc. (Nasdaq:MGX)
Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development. The company's metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. Metagenomi forges these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific, and have a decreased risk of the immune response. Metagenomi's goal is to revolutionize gene editing for the benefit of patients around the world. The company was founded in 2018 and is headquartered in Emeryville, California.
5959 Horton Street
7th floor
Emeryville, California 94608
200
$12.00
11.60 - 12.05
9.74 - 12.74
373.45K
464.18K (02/29/24)
2.38%
$442.08M
$17.2M
-$43.59M
N/A
|
Chairman Jürgen Eckhardt MD, MBA |
|
President, Chief Operating Officer & Director Jian Irish PhD, MBA |
|
Chief Executive Officer & Director Brian C Thomas PhD |
|
Director Willard H Dere MD |
|
Director Sebastián Bernales PhD |
|
Director Risa Stack PhD |
| Date | Form | Event |
|---|---|---|
| 10 Dec, 2024 | 8-K | |
| 6 Dec, 2024 | 4 | |
| 13 Nov, 2024 | 10-Q | |
| 13 Nov, 2024 | 8-K | |
| 6 Nov, 2024 | SC 13G | |
| 6 Sep, 2024 | 4 | |
| 3 Sep, 2024 | 8-K | |
| 14 Aug, 2024 | 8-K | |
| 14 Aug, 2024 | 10-Q | |
| 14 May, 2024 | 8-K | |
| 14 May, 2024 | 10-Q | |
| 10 May, 2024 | SC 13G | |
| 1 May, 2024 | 8-K | |
| 3 Apr, 2024 | 4 | |
| 3 Apr, 2024 | 4 | |
| 3 Apr, 2024 | 4 | |
| 3 Apr, 2024 | 4 | |
| 3 Apr, 2024 | 4 | |
| 3 Apr, 2024 | 4 | |
| 3 Apr, 2024 | 4 | |
| 3 Apr, 2024 | 4 | |
| 3 Apr, 2024 | 4 | |
| 3 Apr, 2024 | 4 | |
| 3 Apr, 2024 | 4 | |
| 27 Mar, 2024 | 10-K | |
| 27 Mar, 2024 | 8-K | |
| 15 Feb, 2024 | 3 | |
| 15 Feb, 2024 | 4 | |
| 15 Feb, 2024 | 4 | |
| 14 Feb, 2024 | 4 | |
| 13 Feb, 2024 | 8-K | |
| 12 Feb, 2024 | 424B4 | IPO completed |
| 9 Feb, 2024 | S-8 | |
| 8 Feb, 2024 | 3 | |
| 8 Feb, 2024 | 3 | |
| 8 Feb, 2024 | 3 | |
| 8 Feb, 2024 | 3 | |
| 8 Feb, 2024 | 3 | |
| 8 Feb, 2024 | 3 | |
| 8 Feb, 2024 | 3 | |
| 8 Feb, 2024 | 3 | |
| 8 Feb, 2024 | 3 | |
| 8 Feb, 2024 | 3 | |
| 8 Feb, 2024 | CERT | |
| 8 Feb, 2024 | 3 | |
| 8 Feb, 2024 | 3 | |
| 8 Feb, 2024 | EFFECT | |
| 8 Feb, 2024 | SEC STAFF | |
| 7 Feb, 2024 | CORRESP | |
| 7 Feb, 2024 | S-1/A | |
| 6 Feb, 2024 | UPLOAD | |
| 6 Feb, 2024 | CORRESP | |
| 6 Feb, 2024 | CORRESP | |
| 5 Feb, 2024 | CORRESP | |
| 5 Feb, 2024 | S-1/A | |
| 5 Feb, 2024 | 8-A12B | |
| 18 Jan, 2024 | CORRESP | |
| 16 Jan, 2024 | CORRESP | |
| 8 Jan, 2024 | S-1/A | |
| 5 Jan, 2024 | CORRESP | |
| 5 Jan, 2024 | S-1 | |
| 20 Dec, 2023 | UPLOAD | |
| 11 Dec, 2023 | DRS/A | |
| 18 Sep, 2023 | SEC STAFF | |
| 7 Sep, 2023 | DRSLTR | |
| 7 Sep, 2023 | DRS/A | |
| 31 Aug, 2023 | UPLOAD | |
| 3 Aug, 2023 | DRS | |
| 11 Jan, 2023 | D | |
| 7 Feb, 2022 | D | |
| 29 Mar, 2021 | D |
Sign Up to Subscribe
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.